Endo International plc: Endo Presents New XIAFLEX (collagenase clostridium histolyticum) Data Analysis at Sexual Medicine Society of North America (SMSNA) Annual Meeting

DUBLIN, Oct. 22, 2021 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) announced today that new post-hoc data from two Phase 3 studies of XIAFLEX (collagenase clostridium histolyticum,

Related Keywords

Arizona ,United States ,Canada ,Dublin ,Ireland ,Canadian ,Landon Trost ,Michaelp Mclane ,Matthew Ziegelmann ,Matthewj Ziegelmann ,Genzhou Liu ,Exchange Commission ,Endo Pharmaceuticals Inc ,Linkedin ,Endo International ,Drug Administration ,Psexual Medicine Society Of North America ,Nasdaq ,Sexual Medicine Society ,North America ,Clostridium Histolyticum Treatment ,Cumulative Benefits After Each Injection ,Fall Scientific Meeting ,About Peyronie ,Important Safety ,Risk Evaluation ,Mitigation Strategy ,Including Anaphylaxis ,Abnormal Coagulation ,Post Injection Back Pain Reactions ,Prescribing Information ,Boxed Warning ,Private Securities Litigation Reform Act ,Electronic Data Analysis ,Endo Pharmaceuticals ,Kendo ,Nternational ,Presents ,Xiaflex ,Collagenase ,Clostridium ,Istolyticum ,Data ,Analysis ,Isexual ,Medicine ,Society ,North ,America ,Msna ,Nnual ,Meeting ,